"HIV within the House Ball Community and the Promise of Community-based Social Structures for Intervention and Support"
Authors: Izu L, Shimkunas R, Jian Z, Hegyi B, Kazemi-Lari M, Baker A, Shaw J, Banyasz T, Chen-Izu Y
TO REMOVE
Authors: Cohen JB, Yang W, Li L, Zhang X, Zheng Z, Orlandi P, Bansal N, Deo R, Lash JP, Rahman M, He J, Shafi T, Chen J, Cohen DL, Matsushita K, Shlipak MG, Wolf M, Go AS, Feldman HI, CRIC Study Investigators
Journal of clinical gastroenterology
Authors: Imperiale TF, Daggy JK, Imler TD, Sherer EA, Kahi CJ, Larson J, Cardwell J, Johnson CS, Ahnen DJ, Antaki F, Ashley C, Baffy G, Dominitz JA, Hou J, Korsten MA, Nagar A, Promrat K, Robertson DJ, Saini S, Shergill A, Smalley WE
Annals of the rheumatic diseases
Authors: Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, Strangfeld A, Gossec L, Carmona L, Mateus EF, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Pons-Estel GJ, Isnardi CA, Berbotto GA, Hsu TY, D'Silva KM, Patel NJ, Kearsley-Fleet L, Schäfer M, Ribeiro SLE, Al Emadi S, Tidblad L, Scirè CA, Raffeiner B, Thomas T, Flipo RM, Avouac J, Seror R, Bernardes M, Cunha MM, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, Souza VA, Mota LMHD, Gomides APM, Dieudé P, Nikiphorou E, Kronzer VL, Singh N, Ugarte-Gil MF, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Yazdany J, COVID-19 Global Rheumatology Alliance
TO REMOVE
Authors: Ix JH, Shlipak MG
ACR Open Rheumatology
Authors: Hwang MC, Lee M, Gensler LS, Ward MM, Brown MA, Learch TJ, Tahanan A, Rahbar MH, Ishimori M, Weisman MH, Reveille JD, PSOAS Study Investigators
European heart journal. Cardiovascular pharmacotherapy
Authors: Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M
PloS one
Authors: Leddy AM, Zakaras JM, Shieh J, Conroy AA, Ofotokun I, Tien PC, Weiser SD
JACC. Cardiovascular interventions
Authors: Teng AE, Yang J, Zimmet JM, Shunk KA
Coronary artery disease
Authors: Bortnick AE, Shitole SG, Hashim H, Khullar P, Park M, Weinreich M, Seibert S, Rauch J, Weisz G, Kizer JR
BACKGROUND
Higher residual anatomic disease was associated with increased mortality in a recent randomized controlled trial of revascularization after ST-elevation myocardial infarction (STEMI). Less is known about the impact of residual disease post-STEMI in race-ethnic minorities.
METHODS
Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX)- II (SS-II) score is an established scoring method for anatomic disease and prevalent co-morbidities to describe patient complexity. We evaluated residual (r) SS-II in 165 patients from a single center urban US registry (n = 1208) presenting for primary percutaneous coronary intervention of STEMI and treated for 3-vessel or left main and any combination of 0, 1, 2 or 3-vessel disease.
RESULTS
The median age was 62 years (IQR 52-70), 29.1% women, 44.9% Hispanic/Latino and 19.4% non-Hispanic Black. Over median of 4.9 years (IQR 2.9-6.3), higher rSS-II was associated with increased death [hazard ratio 2.46 per SD increment in log rSS-II (~1.five-fold increment on the original scale) 95% CI 1.51, 3.99], death or all-cause readmission (hazard ratio 1.37 per SD increment in log rSS-II 95% CI, 1.11-1.70) and death or cardiovascular disease readmission (hazard rati 1.46 per SD increment in log rSS-II 95% CI, 1.14-1.88). rSS-II was higher in older women with more co-morbidities, but not different by race-ethnicity.
CONCLUSIONS
In summary, higher rSS-II was associated with long-term outcomes post-STEMI in a prospective urban, minority cohort, suggesting a potential role for risk stratification with this measure in a non-trial setting.
View on PubMed
